

## Data Sharing Statement

<b>Article Info</b>	<a href="https://dx.doi.org/10.21037/atm-22-3690">https://dx.doi.org/10.21037/atm-22-3690</a>	
<b>Item</b>	<b>Question</b>	<b>Authors' Response (place "-" if not applicable)</b>
1	Would you like to share data collected for your study to others?	Yes.
2	If not, would you like to share the reason for your decision?	-
3	What data in particular will be shared?	The survival data and safety data will be shared.
4	Any other documents will be shared? Such as study protocol, statistical analysis plan, informed consent form, clinical study report, analytic code.	Study protocol, statistical analysis plan, informed consent form, and clinical study report will also be shared if requested.
5	When will data availability begin?	From the publication date.
6	When will data availability end?	One year within the publication date.
7	To whom will you share the data?	Medical oncologists.
8	For what type of analysis or purpose?	For analysis to evaluate the efficacy and safety of anti-programmed cell death protein 1 (PD-1) antibodies plus regorafenib in refractory proficient mismatch repair (pMMR) or microsatellite stable (MSS) metastatic colorectal cancer (mCRC)
9	How or where can the data/documents be obtained?	The database used and/or analyzed during the current study is not publicly available (to maintain privacy) but can be available from the corresponding author on reasonable request. Emails could be sent to the address below to obtain the shared data: 81140568@qq.com
10	Any other restrictions?	We may balance the potential benefits and risks for each request and then provide the data that could be shared.